clevidipine has been researched along with indinavir sulfate in 2 studies
| Studies (clevidipine) | Trials (clevidipine) | Recent Studies (post-2010) (clevidipine) | Studies (indinavir sulfate) | Trials (indinavir sulfate) | Recent Studies (post-2010) (indinavir sulfate) |
|---|---|---|---|---|---|
| 127 | 19 | 62 | 1,834 | 328 | 146 |
| Protein | Taxonomy | clevidipine (IC50) | indinavir sulfate (IC50) |
|---|---|---|---|
| Gag-Pol polyprotein | Human immunodeficiency virus type 1 (BRU ISOLATE) | 0.0004 | |
| Gag polyprotein | HIV-1 M:B_MN | 0.02 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 0.2 | |
| Gag-Pol polyprotein | Human immunodeficiency virus type 1 (NEW YORK-5 ISOLATE) | 0.0261 | |
| Substance-K receptor | Homo sapiens (human) | 5.101 | |
| Thromboxane-A synthase | Homo sapiens (human) | 1.851 | |
| Protease | Human immunodeficiency virus 1 | 0.0349 | |
| Multidrug and toxin extrusion protein 2 | Homo sapiens (human) | 7.8 | |
| Multidrug and toxin extrusion protein 1 | Homo sapiens (human) | 3.8 | |
| Protease | Human immunodeficiency virus 1 | 0.0044 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for clevidipine and indinavir sulfate
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for clevidipine and indinavir sulfate
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |